{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:19:44Z","timestamp":1792189184455,"version":"4.4.0"},"reference-count":76,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T00:00:00Z","timestamp":1708473600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Intensive Medicine"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.jointm.2024.01.005","type":"journal-article","created":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T03:50:08Z","timestamp":1710561008000},"page":"299-306","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["Fungal infections in immunocompromised critically ill patients"],"prefix":"10.1016","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2542-7601","authenticated-orcid":false,"given":"Jos\u00e9","family":"Garnacho-Montero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Barrero-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Le\u00f3n-Moya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jointm.2024.01.005_bib0001","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1007\/s00134-017-4884-z","article-title":"The intensive care medicine research agenda on critically ill oncology and hematology patients","volume":"43","author":"Azoulay","year":"2017","journal-title":"Intensive Care Medicine"},{"issue":"4","key":"10.1016\/j.jointm.2024.01.005_bib0002","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3390\/jof3040057","article-title":"Global and multi-national prevalence of fungal diseases-estimate precision","volume":"3","author":"Bongomin","year":"2017","journal-title":"Journal of Fungi (Basel)"},{"issue":"12","key":"10.1016\/j.jointm.2024.01.005_bib0003","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.medin.2021.08.005","article-title":"Determinants of mortality in cancer patients with unscheduled admission to the Intensive Care Unit: a prospective multicenter study","volume":"46","author":"Cant\u00f3n-Bulnes","year":"2022","journal-title":"Medicina Intensiva"},{"issue":"12","key":"10.1016\/j.jointm.2024.01.005_bib0004","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1007\/s00134-017-4947-1","article-title":"Acute hypoxemic respiratory failure in immunocompromised patients: the Efraim multinational prospective cohort study","volume":"43","author":"Azoulay","year":"2017","journal-title":"Intensive Care Medicine"},{"issue":"2","key":"10.1016\/j.jointm.2024.01.005_bib0005","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s00134-019-05906-5","article-title":"Diagnosis of severe respiratory infections in immunocompromised patients","volume":"46","author":"Azoulay","year":"2020","journal-title":"Intensive Care Medicine"},{"issue":"2","key":"10.1016\/j.jointm.2024.01.005_bib0006","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/QCO.0000000000000043","article-title":"Approach to invasive pulmonary aspergillosis in critically ill patients","volume":"27","author":"Koulenti","year":"2014","journal-title":"Current Opinion in Infectious Diseases"},{"issue":"2","key":"10.1016\/j.jointm.2024.01.005_bib0007","first-page":"173","article-title":"Epidemiology, diagnosis and treatment of fungal respiratory infections in the critically ill patient","volume":"26","author":"Garnacho-Montero","year":"2013","journal-title":"Revista Espa\u00f1ola de Quimioterapia"},{"issue":"1","key":"10.1016\/j.jointm.2024.01.005_bib0008","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13613-021-00827-3","article-title":"New clinical algorithm including fungal biomarkers to better diagnose probable invasive pulmonary aspergillosis in ICU","volume":"11","author":"Hamam","year":"2021","journal-title":"Annals of Intensive Care"},{"issue":"7","key":"10.1016\/j.jointm.2024.01.005_bib0009","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.3855\/jidc.13135","article-title":"Molecular typing and antifungal susceptibility study of Aspergillus spp. in intensive care unit (ICU) patients in Indonesia","volume":"15","author":"Rozaliyani","year":"2021","journal-title":"The Journal of Infection in Developing Countries"},{"issue":"1","key":"10.1016\/j.jointm.2024.01.005_bib0010","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1086\/323335","article-title":"Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus","volume":"34","author":"Ascioglu","year":"2002","journal-title":"Clinical Infectious Diseases"},{"issue":"Suppl 2","key":"10.1016\/j.jointm.2024.01.005_bib0011","article-title":"EORTC\/MSGERC definitions of invasive fungal diseases: summary of activities of the intensive care unit working group","volume":"72","author":"Bassetti","year":"2021","journal-title":"Clinical Infectious Diseases"},{"issue":"8","key":"10.1016\/j.jointm.2024.01.005_bib0012","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.medin.2022.02.011","article-title":"Pulmonary aspergillosis in the intensive care unit: an underdiagnosed disease","volume":"46","author":"Estella","year":"2022","journal-title":"Medicina Intensiva"},{"issue":"3","key":"10.1016\/j.jointm.2024.01.005_bib0013","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.cmi.2023.08.013","article-title":"Lung and sinus fungal infection imaging in immunocompromised patients","volume":"30","author":"Lamoth","year":"2024","journal-title":"Clinical Microbiology and Infection"},{"issue":"Suppl 1","key":"10.1016\/j.jointm.2024.01.005_bib0014","doi-asserted-by":"crossref","first-page":"S147","DOI":"10.1080\/13693780500064771","article-title":"The radiological spectrum of pulmonary aspergillosis","volume":"43","author":"Greene","year":"2005","journal-title":"Medical Mycology"},{"issue":"Suppl 2","key":"10.1016\/j.jointm.2024.01.005_bib0015","article-title":"Guidance on imaging for invasive pulmonary aspergillosis and mucormycosis: from the imaging working group for the revision and update of the consensus definitions of fungal disease from the EORTC\/MSGERC","volume":"72","author":"Alexander","year":"2021","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.jointm.2024.01.005_bib0016","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12941-023-00626-7","article-title":"Microbiological diagnosis of pulmonary invasive aspergillosis in critically ill patients with severe SARS-CoV-2 pneumonia: a bronchoalveolar study","volume":"22","author":"Estella","year":"2023","journal-title":"Annals of Clinical Microbiology and Antimicrobials"},{"issue":"1","key":"10.1016\/j.jointm.2024.01.005_bib0017","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1164\/rccm.200704-606OC","article-title":"Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients","volume":"177","author":"Meersseman","year":"2008","journal-title":"The American Journal of Respiratory and Critical Care Medicine"},{"issue":"1","key":"10.1016\/j.jointm.2024.01.005_bib0018","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1128\/JCM.05267-11","article-title":"Diagnostic accuracy of serum 1,3-\u03b2-d-glucan for pneumocystis jiroveci pneumonia, invasive candidiasis, and invasive aspergillosis: systematic review and meta-analysis","volume":"50","author":"Onishi","year":"2012","journal-title":"The Journal of Clinical Microbiology"},{"key":"10.1016\/j.jointm.2024.01.005_bib0019","doi-asserted-by":"crossref","first-page":"21484","DOI":"10.18632\/oncotarget.7471","article-title":"(1, 3)-\u03b2-d-glucan assay for diagnosing invasive fungal infections in critically ill patients with hematological malignancies","volume":"7","author":"Azoulay","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.jointm.2024.01.005_bib0020","article-title":"The comparative evaluation of the fujifilm wako \u03b2-glucan assay and fungitell assay for diagnosing invasive fungal disease","volume":"9","author":"Singh","year":"2022","journal-title":"Journal of Fungi (Basel)"},{"issue":"7","key":"10.1016\/j.jointm.2024.01.005_bib0021","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0236095","article-title":"Comparative performance evaluation of Wako \u03b2-glucan test and Fungitell assay for the diagnosis of invasive fungal diseases","volume":"15","author":"De Carolis","year":"2020","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.jointm.2024.01.005_bib0022","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.3390\/diagnostics12112712","article-title":"Invasive aspergillosis in the intensive care unit","volume":"12","author":"Townsend","year":"2022","journal-title":"Diagnostics (Basel)"},{"issue":"Suppl 2","key":"10.1016\/j.jointm.2024.01.005_bib0023","article-title":"Defining galactomannan positivity in the updated EORTC\/MSGERC consensus definitions of invasive fungal diseases","volume":"72","author":"Mercier","year":"2021","journal-title":"Clinical Infectious Diseases"},{"issue":"Suppl 1","key":"10.1016\/j.jointm.2024.01.005_bib0024","article-title":"Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clinical Microbiology and Infection"},{"issue":"2","key":"10.1016\/j.jointm.2024.01.005_bib0025","article-title":"Current and future pathways in aspergillus diagnosis","volume":"12","author":"Dobi\u00e1\u0161","year":"2023","journal-title":"Antibiotics (Basel)"},{"issue":"4","key":"10.1016\/j.jointm.2024.01.005_bib0026","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s12281-020-00409-z","article-title":"The Aspergillus lateral flow assay for the diagnosis of invasive aspergillosis: an update","volume":"14","author":"Jenks","year":"2020","journal-title":"Current Fungal Infection Reports"},{"issue":"6","key":"10.1016\/j.jointm.2024.01.005_bib0027","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1128\/JCM.00467-14","article-title":"Performance of galactomannan, beta-d-glucan, Aspergillus lateral-flow device, conventional culture, and PCR tests with bronchoalveolar lavage fluid for diagnosis of invasive pulmonary aspergillosis","volume":"52","author":"Hoenigl","year":"2014","journal-title":"The Journal of Clinical Microbiology"},{"issue":"7","key":"10.1016\/j.jointm.2024.01.005_bib0028","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa1281","article-title":"Performance of the bronchoalveolar lavage fluid Aspergillus Galactomannan lateral flow assay with cube reader for diagnosis of invasive pulmonary aspergillosis: a multicenter cohort study","volume":"73","author":"Jenks","year":"2021","journal-title":"Clinical Infectious Diseases"},{"issue":"1","key":"10.1016\/j.jointm.2024.01.005_bib0029","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.diagmicrobio.2018.08.005","article-title":"The performance of galactomannan in combination with 1,3-\u03b2-d-glucan or aspergillus-lateral flow device for the diagnosis of invasive aspergillosis: evidences from 13 studies","volume":"93","author":"Zhang","year":"2019","journal-title":"Diagnostic Microbiology and Infectious Disease"},{"key":"10.1016\/j.jointm.2024.01.005_bib0030","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1471-2334-13-29","article-title":"Aspergillosis in Intensive Care Unit (ICU) patients: epidemiology and economic outcomes","volume":"13","author":"Baddley","year":"2013","journal-title":"BMC Infectious Diseases"},{"issue":"4","key":"10.1016\/j.jointm.2024.01.005_bib0031","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/cid\/ciw444","article-title":"Executive summary: practice guidelines for the diagnosis and management of Aspergillosis: 2016 update by the infectious diseases society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clinical Infectious Diseases"},{"issue":"3","key":"10.1016\/j.jointm.2024.01.005_bib0032","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3324\/haematol.2016.152900","article-title":"ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients","volume":"102","author":"Tissot","year":"2017","journal-title":"Haematologica"},{"issue":"Suppl 7","key":"10.1016\/j.jointm.2024.01.005_bib0033","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/imj.15591","article-title":"Consensus guidelines for the diagnosis and management of invasive aspergillosis, 2021","volume":"51","author":"Douglas","year":"2021","journal-title":"The Internal Medicine Journal"},{"issue":"8","key":"10.1016\/j.jointm.2024.01.005_bib0034","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.eimc.2018.03.018","article-title":"Executive summary of clinical practice guideline for the management of invasive diseases caused by Aspergillus: 2018 update by the GEMICOMED-SEIMC\/REIPI","volume":"37","author":"Garcia-Vidal","year":"2019","journal-title":"Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"},{"issue":"6","key":"10.1016\/j.jointm.2024.01.005_bib0035","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"The New England Journal of Medicine"},{"issue":"12","key":"10.1016\/j.jointm.2024.01.005_bib0036","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1007\/s00134-019-05789-6","article-title":"Invasive pulmonary aspergillosis in critically ill patients with hematological malignancies","volume":"45","author":"Pardo","year":"2019","journal-title":"Intensive Care Medicine"},{"issue":"10","key":"10.1016\/j.jointm.2024.01.005_bib0037","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1007\/s00134-011-2344-8","article-title":"Outcomes of mechanically ventilated hematology patients with invasive pulmonary aspergillosis","volume":"37","author":"Burghi","year":"2011","journal-title":"Intensive Care Medicine"},{"issue":"10020","key":"10.1016\/j.jointm.2024.01.005_bib0038","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"issue":"10273","key":"10.1016\/j.jointm.2024.01.005_bib0039","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0140-6736(21)00219-1","article-title":"Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial","volume":"397","author":"Maertens","year":"2021","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jointm.2024.01.005_bib0040","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3390\/antibiotics10050487","article-title":"Therapeutic drug monitoring of isavuconazole: serum concentration variability and success rates for reaching target in comparison with voriconazole","volume":"10","author":"Risum","year":"2021","journal-title":"Antibiotics (Basel)"},{"issue":"7","key":"10.1016\/j.jointm.2024.01.005_bib0041","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/myc.13469","article-title":"Isavuconazole therapeutic drug monitoring in critically ill ICU patients: a monocentric retrospective analysis","volume":"65","author":"H\u00f6hl","year":"2022","journal-title":"Mycoses"},{"issue":"2","key":"10.1016\/j.jointm.2024.01.005_bib0042","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3390\/jof9020211","article-title":"Population pharmacokinetics of isavuconazole in critical care patients with COVID-19-associated pulmonary aspergillosis and Monte Carlo simulations of high off-label doses","volume":"9","author":"Perez","year":"2023","journal-title":"Journal of Fungi (Basel)"},{"issue":"10","key":"10.1016\/j.jointm.2024.01.005_bib0043","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1007\/s00436-015-4678-6","article-title":"Pneumocystis jirovecii\u2013from a commensal to pathogen: clinical and diagnostic review","volume":"114","author":"Sokulska","year":"2015","journal-title":"Parasitology Research"},{"issue":"1","key":"10.1016\/j.jointm.2024.01.005_bib0044","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1186\/s13054-018-2221-8","article-title":"Clinical course, treatment and outcome of Pneumocystis pneumonia in immunocompromised adults: a retrospective analysis over 17 years","volume":"22","author":"Schmidt","year":"2018","journal-title":"Critical Care"},{"issue":"1","key":"10.1016\/j.jointm.2024.01.005_bib0045","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1186\/s13054-023-04608-1","article-title":"Pneumocystis jirovecii pneumonia in intensive care units: a multicenter study by ESGCIP and EFISG","volume":"27","author":"Giacobbe","year":"2023","journal-title":"Critical Care"},{"issue":"2","key":"10.1016\/j.jointm.2024.01.005_bib0046","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1378\/chest.108.2.415","article-title":"Serum lactate dehydrogenase (LDH) in Pneumocystis carinii pneumonia, tuberculosis, and bacterial pneumonia","volume":"108","author":"Quist","year":"1995","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.jointm.2024.01.005_bib0047","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1378\/chest.08-1309","article-title":"Polymerase chain reaction for diagnosing pneumocystis pneumonia in non-HIV immunocompromised patients with pulmonary infiltrates","volume":"135","author":"Azoulay","year":"2009","journal-title":"Chest"},{"issue":"7","key":"10.1016\/j.jointm.2024.01.005_bib0048","doi-asserted-by":"crossref","first-page":"663","DOI":"10.3390\/jof8070663","article-title":"Usefulness of \u00df-D-glucan assay for the first-line diagnosis of pneumocystis pneumonia and for discriminating between pneumocystis colonization and pneumocystis pneumonia","volume":"8","author":"Bigot","year":"2022","journal-title":"Journal of Fungi (Basel)"},{"issue":"6","key":"10.1016\/j.jointm.2024.01.005_bib0049","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1128\/JCM.03174-15","article-title":"Detection of pneumocystis jirovecii by quantitative PCR to differentiate colonization and pneumonia in immunocompromised HIV-positive and HIV-negative patients","volume":"54","author":"Fauchier","year":"2016","journal-title":"The Journal of Clinical Microbiology"},{"issue":"9","key":"10.1016\/j.jointm.2024.01.005_bib0050","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1093\/jac\/dkw158","article-title":"ECIL guidelines for treatment of Pneumocystis jirovecii pneumonia in non-HIV-infected haematology patients","volume":"71","author":"Maschmeyer","year":"2016","journal-title":"The Journal of Antimicrobial Chemotherapy"},{"issue":"8","key":"10.1016\/j.jointm.2024.01.005_bib0051","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1093\/mmy\/myu060","article-title":"Efficacy of caspofungin, a 1,3-\u03b2-d-glucan synthase inhibitor, on Pneumocystis carinii pneumonia in rats","volume":"52","author":"Sun","year":"2014","journal-title":"Medical Mycology"},{"issue":"8","key":"10.1016\/j.jointm.2024.01.005_bib0052","doi-asserted-by":"crossref","first-page":"e70619","DOI":"10.1371\/journal.pone.0070619","article-title":"Therapeutic potential of caspofungin combined with trimethoprim-sulfamethoxazole for pneumocystis pneumonia: a pilot study in mice","volume":"8","author":"Lobo","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jointm.2024.01.005_bib0053","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s40121-021-00586-5","volume":"11","author":"Huang","year":"2022","journal-title":"Infectious Diseases and Therapy"},{"issue":"1","key":"10.1016\/j.jointm.2024.01.005_bib0054","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1186\/s12879-023-08372-z","article-title":"Efficacy of initial caspofungin plus trimethoprim\/sulfamethoxazole for severe PCP in patients without human immunodeficiency virus infection","volume":"23","author":"Qi","year":"2023","journal-title":"BMC Infectious Diseases"},{"issue":"10","key":"10.1016\/j.jointm.2024.01.005_bib0055","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.cmi.2023.05.004","article-title":"Which trial do we need? Combination treatment of Pneumocystis jirovecii pneumonia in non-HIV infected patients","volume":"29","author":"Koehler","year":"2023","journal-title":"Clinical Microbiology and Infection"},{"issue":"4","key":"10.1016\/j.jointm.2024.01.005_bib0056","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006150.pub2","article-title":"Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection","volume":"2015","author":"Ewald","year":"2015","journal-title":"The Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1016\/j.jointm.2024.01.005_bib0057","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13613-019-0539-2","article-title":"Candidemia in critically ill immunocompromised patients: report of a retrospective multicenter cohort study","volume":"9","author":"Ghrenassia","year":"2019","journal-title":"Ann Intensive Care"},{"issue":"5","key":"10.1016\/j.jointm.2024.01.005_bib0058","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1007\/s00134-017-4743-y","article-title":"The risk and clinical outcome of candidemia depending on underlying malignancy","volume":"43","author":"Lortholary","year":"2017","journal-title":"Intensive Care Medicine"},{"issue":"9","key":"10.1016\/j.jointm.2024.01.005_bib0059","doi-asserted-by":"crossref","first-page":"913","DOI":"10.3390\/jof9090913","article-title":"An overview on Candida auris in healthcare settings","volume":"9","author":"Cristina","year":"2023","journal-title":"Journal of Fungi (Basel)"},{"issue":"3","key":"10.1016\/j.jointm.2024.01.005_bib0060","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1086\/338404","article-title":"Pulmonary candidiasis in patients with cancer: an autopsy study","volume":"34","author":"Kontoyiannis","year":"2002","journal-title":"Clinical Infectious Diseases"},{"issue":"12","key":"10.1016\/j.jointm.2024.01.005_bib0061","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.3390\/antibiotics11121804","article-title":"How to identify invasive Candidemia in ICU-A narrative review","volume":"11","author":"Alves","year":"2022","journal-title":"Antibiotics (Basel)"},{"issue":"1","key":"10.1016\/j.jointm.2024.01.005_bib0062","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s13054-016-1324-3","article-title":"Contribution of Candida biomarkers and DNA detection for the diagnosis of invasive candidiasis in ICU patients with severe abdominal conditions","volume":"20","author":"Le\u00f3n","year":"2016","journal-title":"Critical Care"},{"issue":"8","key":"10.1016\/j.jointm.2024.01.005_bib0063","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/s00134-012-2616-y","article-title":"Value of \u03b2-d-glucan and Candida albicans germ tube antibody for discriminating between Candida colonization and invasive candidiasis in patients with severe abdominal conditions","volume":"38","author":"Le\u00f3n","year":"2012","journal-title":"Intensive Care Medicine"},{"issue":"11","key":"10.1016\/j.jointm.2024.01.005_bib0064","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1093\/cid\/cix1095","article-title":"Detecting infections rapidly and easily for Candidemia Trial, part 2 (DIRECT2): a prospective, multicenter study of the T2 Candida Panel","volume":"66","author":"Clancy","year":"2018","journal-title":"Clinical Infectious Diseases"},{"issue":"1","key":"10.1016\/j.jointm.2024.01.005_bib0065","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1128\/AAC.00945-09","article-title":"Effect of antifungal therapy timing on mortality in cancer patients with candidemia","volume":"54","author":"Taur","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.jointm.2024.01.005_bib0066","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s00134-019-05599-w","article-title":"ESICM\/ESCMID task force on practical management of invasive candidiasis in critically ill patients","volume":"45","author":"Martin-Loeches","year":"2019","journal-title":"Intensive Care Medicine"},{"issue":"4","key":"10.1016\/j.jointm.2024.01.005_bib0067","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical practice guideline for the management of Candidiasis: 2016 update by the infectious diseases society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clinical Infectious Diseases"},{"issue":"2","key":"10.1016\/j.jointm.2024.01.005_bib0068","doi-asserted-by":"crossref","DOI":"10.1016\/j.mycmed.2023.101362","article-title":"Efficacy and safety of echinocandin monotherapy and combination therapy for immunocompromised patients with systemic candidiasis: a systematic review and meta-analysis","volume":"33","author":"Tang","year":"2023","journal-title":"Journal de Mycologie M\u00e9dicale"},{"issue":"9","key":"10.1016\/j.jointm.2024.01.005_bib0069","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s40265-023-01891-8","article-title":"Rezafungin: first approval","volume":"83","author":"Syed","year":"2023","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.jointm.2024.01.005_bib0070","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13054-020-03265-y","article-title":"(1,3)-\u03b2-d-Glucan-based empirical antifungal interruption in suspected invasive candidiasis: a randomized trial","volume":"24","author":"De Pascale","year":"2020","journal-title":"Critical Care"},{"issue":"11","key":"10.1016\/j.jointm.2024.01.005_bib0071","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1007\/s00134-017-4932-8","article-title":"Biomarker-based strategy for early discontinuation of empirical antifungal treatment in critically ill patients: a randomized controlled trial","volume":"43","author":"Rouz\u00e9","year":"2017","journal-title":"Intensive Care Medicine"},{"issue":"suppl_1","key":"10.1016\/j.jointm.2024.01.005_bib0072","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/mmy\/myx101","article-title":"Challenges in the diagnosis and treatment of mucormycosis","volume":"56","author":"Skiada","year":"2018","journal-title":"Medical Mycology"},{"issue":"4","key":"10.1016\/j.jointm.2024.01.005_bib0073","doi-asserted-by":"crossref","first-page":"ofw209","DOI":"10.1093\/ofid\/ofw209","article-title":"A potential explanation of a positive serum \u03b2-glucan assay in mucormycosis","volume":"3","author":"Kontoyiannis","year":"2016","journal-title":"Open Forum Infectious Diseases"},{"issue":"12","key":"10.1016\/j.jointm.2024.01.005_bib0074","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(19)30312-3","article-title":"Global guideline for the diagnosis and management of mucormycosis: an initiative of the European confederation of medical mycology in cooperation with the Mycoses study group education and research consortium","volume":"19","author":"Cornely","year":"2019","journal-title":"The Lancet Infectious Diseases"},{"issue":"7","key":"10.1016\/j.jointm.2024.01.005_bib0075","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","article-title":"Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis","volume":"16","author":"Marty","year":"2016","journal-title":"The Lancet Infectious Diseases"},{"issue":"15","key":"10.1016\/j.jointm.2024.01.005_bib0076","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s40265-021-01611-0","article-title":"The antifungal pipeline: fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin","volume":"81","author":"Hoenigl","year":"2021","journal-title":"Drugs"}],"container-title":["Journal of Intensive Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667100X2400015X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667100X2400015X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T22:08:22Z","timestamp":1718662102000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667100X2400015X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":76,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S2667100X2400015X"],"URL":"https:\/\/doi.org\/10.1016\/j.jointm.2024.01.005","relation":{},"ISSN":["2667-100X"],"issn-type":[{"value":"2667-100X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fungal infections in immunocompromised critically ill patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Intensive Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jointm.2024.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of Chinese Medical Association.","name":"copyright","label":"Copyright"}]}}